Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API

Cancer Risks and Factors

40 ta ish

  1. RISK FACTORS AND PREVENTION OF ENDOMETRIAL CANCER

    Nozimakhon Marufjonova, Gulcharos Azimova, Malika Farmonova

    MaqolaCancer Risks and FactorsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  2. RISK FACTORS AND PREVENTION OF ENDOMETRIAL CANCER

    Nozimakhon Marufjonova, Gulcharos Azimova, Malika Farmonova

    MaqolaCancer Risks and FactorsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  3. RESULTS OF MORPHOLOGICAL AND MORPHOMETRIC CHANGES IN THE RECTUM AS A RESULT OF CHEMOTHERAPY IN EXPERIMENTAL BREAST CANCER

    Shakhlo Uktamovna Ashurova, Elena Alexandrovna Kharibova

    MaqolaCancer Risks and FactorsOpen MIND20260 iqtibos
    ABI

  4. RESULTS OF MORPHOLOGICAL AND MORPHOMETRIC CHANGES IN THE RECTUM AS A RESULT OF CHEMOTHERAPY IN EXPERIMENTAL BREAST CANCER

    Shakhlo Uktamovna Ashurova, Elena Alexandrovna Kharibova

    MaqolaCancer Risks and FactorsZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  5. MORPHOLOGICAL FEATURES OF THE RECTUM DURING CHEMOTHERAPY AFTER MODELING BREAST CANCER

    Shakhlo Uktamovna Ashurova, Elena Aleksandrovna Kharibova

    MaqolaBreast Cancer Treatment StudiesOpen MIND20260 iqtibos
    ABI

  6. MORPHOLOGICAL FEATURES OF THE RECTUM DURING CHEMOTHERAPY AFTER MODELING BREAST CANCER

    Shakhlo Uktamovna Ashurova, Elena Aleksandrovna Kharibova

    MaqolaBreast Cancer Treatment StudiesZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  7. 208 Correlation of HER2 FISH Status with Hormone Receptors, Ki-67, and Histologic Grade in Breast Carcinomas with HER2 IHC 2+ among Women in Uzbekistan

    Mirzabek Shodmonov Isokul Ugli, Madina Jakhongirova, Natalya Pak +3

    MaqolaHER2/EGFR in Cancer ResearchLaboratory Investigation20260 iqtibos
    ABI

  8. A Modern Perspective on Gestational and Perinatal Outcomes in Fetal Macrosomia

    Safarova Lola Aliaskarovna, Vafoyeva Shoira Shavkatovna

    MaqolaGestational Diabetes Research and ManagementThe American Journal of Medical Sciences and Pharmaceutical Research20260 iqtibos
    ABI

  9. Molecular Mechanisms of Mammary Carcinogenesis: Current Understanding and Prospects for Targeted Therapy

    Ruzibakieva M.R., Jangavorov A.J., Ramziddinov J.J. +2

    MaqolaAdvanced Breast Cancer TherapiesInternational Journal of Medical Science and Public Health Research20260 iqtibos
    ABI

  10. A Modern Perspective on Gestational and Perinatal Outcomes in Fetal Macrosomia

    Safarova Lola Aliaskarovna, Vafoyeva Shoira Shavkatovna

    MaqolaGestational Diabetes Research and ManagementThe American Journal of Medical Sciences and Pharmaceutical Research20260 iqtibos
    ABI

  11. Exercise and Regulation of PI3K/Akt/mTOR and AMPK Pathways in Cancer: Molecular Mechanisms and Therapeutic Implications: A Narrative Review

    Abeer Issa Mohammed, Ochilova Gulrux Saidovna, Davron Makhmudov +11

    MaqolaMetabolism, Diabetes, and CancerAsian Pacific Journal of Cancer Care20260 iqtibos
    ABI

  12. POSTPARTUM OBESITY AND METHODS OF NUTRITIONAL CORRECTION

    Gulnozakhon Mukhidin kizi Ruzimatova

    MaqolaGestational Diabetes Research and ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  13. POSTPARTUM OBESITY AND METHODS OF NUTRITIONAL CORRECTION

    Gulnozakhon Mukhidin kizi Ruzimatova

    MaqolaGestational Diabetes Research and ManagementZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  14. CLINICAL AND DIAGNOSTIC FEATURES OF BENIGN CERVICAL DISEASES DURING PREGNANCY

    Aziza Jumaniyazova

    MaqolaCervical Cancer and HPV ResearchZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI

  15. CLINICAL AND DIAGNOSTIC FEATURES OF BENIGN CERVICAL DISEASES DURING PREGNANCY

    Aziza Jumaniyazova

    MaqolaCervical Cancer and HPV ResearchZenodo (CERN European Organization for Nuclear Research)20260 iqtibos
    ABI